Canbas (4575.T) traded up 1.8 % during a 24 hours period ending at 05:36 AM Central Europe on Tuesday 27th. One Canbas stock can currently be bought for about JPY 736 on popular exchanges. Current supply of Canbas stocks is 19.1 mn. Canbas has a current market capitalization of JPY 14.1 bn and approximately JPY 100.2 mn worth of Canbas was traded on exchanges in the last 24 hours. Since last month end, Canbas has traded 0.27 % up. Simple moving average of last 200 days is at JPY 744.62. The highest price of past 52 weeks was recorded at JPY 991 on 02/03/2026. 52 weeks low was at JPY 506 on 06/10/2026.

Here is how related stocks have performed in the past 24 hours:

  • Medius (3154.T) traded up 0.13 % and now trades at JPY 748. Current market capitalisation for Medius is JPY 16.8 bn. Current price/earnings ratio for Medius is 17.79.

  • Toho Chemical Industry (4409.T) traded down -1.35 % and now trades at JPY 813. Current market capitalisation for Toho Chemical Industry is JPY 16.8 bn. Current price/earnings ratio for Toho Chemical Industry is 9.74.

  • Nakanishi Manuf (5941.T) traded flat 0 % and now trades at JPY 2,672. Current market capitalisation for Nakanishi Manuf is JPY 16.9 bn. Nakanishi Manuf has a current price to earnings ratio of 39.55.

  • Univance (7254.T) traded up 0.75 % and now trades at JPY 799. Univance has a market capitalisation of JPY 16.8 bn. Current price/earnings ratio for Univance is 13.92.

  • Environment Friendly (3777.T) traded up 2.27 % and now trades at JPY 45. Current market capitalisation for Environment Friendly is JPY 16.7 bn. Current price/earnings ratio for Environment Friendly is 208.23.

About Canbas

CanBas Co., Ltd. is a clinical stage biopharmaceutical company based in Numazu, Japan that specializes in developing therapeutics for cancer patients. The company is actively involved in two main projects: CBP501, a calmodulin modulator for tumor treatment, and CBS9106, a small molecule reversible inhibitor of Exportin-1 currently in Phase I clinical trial for the treatment of solid tumors. CanBas has established a collaboration alliance with Stemline Therapeutics, Inc. The company was founded in 2000.